About Careers Internship MedBlog Contact us
Medindia LOGIN REGISTER
Advertisement

In Patients With Metastatic Prostate Cancer, Noninvasive Assay Monitored Treatment Response

by Bidita Debnath on October 30, 2012 at 10:37 PM
Font : A-A+

 In Patients With Metastatic Prostate Cancer, Noninvasive Assay Monitored Treatment Response

"The growth and survival of prostate cancer cells are very dependent on signals that the cancer cells receive through a protein called the androgen receptor," said Daniel.

Daniel A. Haber, M.D., Ph.D. is the director of the Massachusetts General Hospital Cancer Center in Boston and project leader of the Stand Up To Cancer Bioengineering and Clinical Applications of Circulating Tumor Cell Chip Dream Team. "Treatments that deprive the androgen receptor of its signals are initially highly effective in most patients with metastatic prostate cancer. Unfortunately, prostate cancer, like all cancers, undergoes evolution during therapy, and this can confer resistance to treatment."

Advertisement

Haber and his colleagues established a way to isolate cancer cells from the blood of patients with prostate cancer and to measure readouts of androgen receptor signaling in each of the individual cancer cells in the blood.

Deciding the ideal treatment for patients with metastatic prostate cancer that stops responding to initial therapy could be guided by certain analyses of cancer cells isolated from the patients'' blood, according to data published in Cancer Discovery, a journal of the American Association for Cancer Research.
Advertisement

Prior to the initiation of androgen-deprivation therapy, the androgen receptor signaling pathway was turned on in most of the cancer cells in the blood of patients with newly diagnosed metastatic prostate cancer. After the initiation of androgen-deprivation therapy, the pathway turned off in the circulating tumor cells.

However, in patients whose prostate cancer had progressed after initially responding to androgen-deprivation therapy, the cancer cells in the blood were highly variable. Some cells had the androgen receptor signaling pathway turned on while other cells had it turned off. Yet other cells had characteristics of the signaling pathway being both on and off. The presence of cells with a mixed androgen receptor signaling pattern was associated with an adverse treatment outcome.

In addition, in patients treated with a new drug, abiraterone, which achieves more complete androgen deprivation than earlier treatments, an increased percentage of circulating tumor cells with androgen receptor signaling turned on despite abiraterone treatment was associated with decreased overall survival.

"This study is a proof of principle that it is possible to monitor, in patients with metastatic prostate cancer, the androgen receptor signaling pathway in real time, repeatedly and noninvasively," Haber said. "Our approach allowed us to monitor whether initial androgen-deprivation therapy was keeping the androgen signaling pathway shut down or whether the tumor was becoming resistant, and if so, by what mechanism."

"As more drugs are developed that target the different pathways that drive the recurrence of metastatic prostate cancer in different patients, it will become essential to know which drug and which pathway is relevant in each patient," he said. "Our assay will be an effective way to interrogate the tumor and follow it during the course of treatment to monitor therapy response and the emergence of drug resistance."

This work was supported by the Evans Foundation, the Prostate Cancer Foundation and Stand Up To Cancer.

Source: Newswise
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
What's New on Medindia
Alarming Cesarean Section Trends in India - Convenience or Compulsion of Corporate Healthcare
Quiz on Low-Calorie Diet for Diabetes
World Heart Day in 2022- Use Heart for Every Heart
View all
Recommended Reading
News Archive
Date
Category
News Category

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Prostate Cancer Trans-Urethral Resection of the Prostate Cancer Prostate Cancer: Treatment Options Prostate Specific Antigen [PSA] Medical Management of Prostate Cancer 

Most Popular on Medindia

Daily Calorie Requirements Noscaphene (Noscapine) Turmeric Powder - Health Benefits, Uses & Side Effects Drug Side Effects Calculator A-Z Drug Brands in India Color Blindness Calculator Find a Doctor Post-Nasal Drip How to Reduce School Bag Weight - Simple Tips Drug - Food Interactions
This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use
open close
CONSULT ONLINE WITH A DOCTOR

×

In Patients With Metastatic Prostate Cancer, Noninvasive Assay Monitored Treatment Response Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests